These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 16624686)

  • 21. Long-term low-dose spironolactone therapy is safe in oligoanuric hemodialysis patients.
    Matsumoto Y; Kageyama S; Yakushigawa T; Arihara K; Sugiyama T; Mori Y; Sugiyama H; Ohmura H; Shio N
    Cardiology; 2009; 114(1):32-8. PubMed ID: 19342857
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Spironolactone in type 2 diabetic nephropathy: Effects on proteinuria, blood pressure and renal function.
    van den Meiracker AH; Baggen RG; Pauli S; Lindemans A; Vulto AG; Poldermans D; Boomsma F
    J Hypertens; 2006 Nov; 24(11):2285-92. PubMed ID: 17053552
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Understanding the risk of hyperkalaemia in heart failure: role of aldosterone antagonism.
    Poggio R; Grancelli HO; Miriuka SG
    Postgrad Med J; 2010 Mar; 86(1013):136-42. PubMed ID: 20237007
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [The aldosterone antagonist spironolactone prolongs the survival of chronic heart failure patients. The results of the RALES study. The Randomized Aldactone Evaluation Study].
    Schwinger RH
    Dtsch Med Wochenschr; 1999 Aug; 124(34-35):987-8. PubMed ID: 10488324
    [No Abstract]   [Full Text] [Related]  

  • 25. Sodium retention in heart failure and cirrhosis: potential role of natriuretic doses of mineralocorticoid antagonist?
    Bansal S; Lindenfeld J; Schrier RW
    Circ Heart Fail; 2009 Jul; 2(4):370-6. PubMed ID: 19808361
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adherence to guidelines for patients hospitalized with heart failure: a nationwide survey.
    Jotkowitz AB; Porath A; Shotan A; Mittelman M; Grossman E; Zimlichman R; Lewis BS; Caspi A; Gottlieb S; Garty M;
    Isr Med Assoc J; 2006 Dec; 8(12):875-9. PubMed ID: 17214110
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hyperkalemia after the publication of RALES.
    Newsome BB; Warnock DG
    N Engl J Med; 2004 Dec; 351(23):2448-50; author reply 2448-50. PubMed ID: 15580678
    [No Abstract]   [Full Text] [Related]  

  • 28. Spironolactone use at discharge was associated with improved survival in hospitalized patients with systolic heart failure.
    Hamaguchi S; Kinugawa S; Tsuchihashi-Makaya M; Goto K; Goto D; Yokota T; Yamada S; Yokoshiki H; Takeshita A; Tsutsui H
    Am Heart J; 2010 Dec; 160(6):1156-62. PubMed ID: 21146672
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Race influences the safety and efficacy of spironolactone in severe heart failure.
    Vardeny O; Cavallari LH; Claggett B; Desai AS; Anand I; Rossignol P; Zannad F; Pitt B; Solomon SD;
    Circ Heart Fail; 2013 Sep; 6(5):970-6. PubMed ID: 23940307
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Cost effectiveness of the use of spironolactone in the treatment of chronic heart failure].
    Soto Alvarez J; González Vilchez F
    An Med Interna; 2001 Aug; 18(8):421-5. PubMed ID: 11589080
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Incidence, predictors, and outcomes related to hypo- and hyperkalemia in patients with severe heart failure treated with a mineralocorticoid receptor antagonist.
    Vardeny O; Claggett B; Anand I; Rossignol P; Desai AS; Zannad F; Pitt B; Solomon SD;
    Circ Heart Fail; 2014 Jul; 7(4):573-9. PubMed ID: 24812304
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment of heart failure with spironolactone--trial and tribulations.
    McMurray JJ; O'Meara E
    N Engl J Med; 2004 Aug; 351(6):526-8. PubMed ID: 15295043
    [No Abstract]   [Full Text] [Related]  

  • 33. Hyperkalemia after the publication of RALES.
    Witham MD; Gillespie ND; Struthers AD
    N Engl J Med; 2004 Dec; 351(23):2448-50; author reply 2448-50. PubMed ID: 15580679
    [No Abstract]   [Full Text] [Related]  

  • 34. Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure.
    Anand IS; Bishu K; Rector TS; Ishani A; Kuskowski MA; Cohn JN
    Circulation; 2009 Oct; 120(16):1577-84. PubMed ID: 19805651
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hyperkalemia after the publication of RALES.
    Goldfarb DS
    N Engl J Med; 2004 Dec; 351(23):2448-50; author reply 2448-50. PubMed ID: 15575065
    [No Abstract]   [Full Text] [Related]  

  • 36. Evaluation of the safety and tolerability of spironolactone in patients with heart failure and chronic kidney disease.
    Buckallew AR; Tellor KB; Watson R; Miller W; Mbachu G; Whitlock C; Seltzer JR; Armbruster AL
    Eur J Clin Pharmacol; 2021 Jul; 77(7):955-960. PubMed ID: 33449127
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Cost-benefit analysis of spironolactone use in the treatment of chronic heart failure].
    Alvarez JS; Vílchez FG
    Rev Esp Cardiol; 2001 Feb; 54(2):175-80. PubMed ID: 11181306
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical factors associated with hyperkalemia in patients with congestive heart failure.
    Ramadan FH; Masoodi N; El-Solh AA
    J Clin Pharm Ther; 2005 Jun; 30(3):233-9. PubMed ID: 15896240
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effectiveness and Safety of Aldosterone Antagonist Therapy Use Among Older Patients With Reduced Ejection Fraction After Acute Myocardial Infarction.
    Wang TY; Vora AN; Peng SA; Fonarow GC; Das S; de Lemos JA; Peterson ED
    J Am Heart Assoc; 2016 Jan; 5(1):. PubMed ID: 26796254
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Spironolactone has antiarrhythmic activity in ischaemic cardiac patients without cardiac failure.
    Shah NC; Pringle SD; Donnan PT; Struthers AD
    J Hypertens; 2007 Nov; 25(11):2345-51. PubMed ID: 17921831
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.